LL-37
A human antimicrobial peptide involved in innate immune signaling and host defense.
On this page
WHAT THE EVIDENCE SAYS
LL-37 evidence summary.
LL-37 is an important endogenous host-defense peptide, but complex pro-inflammatory, anti-inflammatory, antimicrobial, and cytotoxic actions make simple immune-support claims misleading.
01 / CLASSIFICATION
What is LL-37?
Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.
02 / EVIDENCE
LL-37 human and preclinical evidence.
The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.
03 / STATUS
LL-37 FDA and sport status.
Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.
04 / RESEARCH AREAS
What is LL-37 being studied for?
05 / COMPARISONS
Compare LL-37.
06 / LATEST & DEFINING SOURCES
LL-37 primary and official sources.
07 / QUESTIONS
Questions about LL-37.
Start with identity, research, human evidence, approval, sport status, and the limits of the current record.
LL-37 is an important endogenous host-defense peptide, but complex pro-inflammatory, anti-inflammatory, antimicrobial, and cytotoxic actions make simple immune-support claims misleading.
Current source-backed research areas include Antimicrobial defense, Innate immunity, Inflammation, Cytotoxicity. These areas describe investigation, not established personal benefit.
Current U.S. status for LL-37: No FDA-approved LL-37 drug product; FDA reports insufficient human safety information for compounded LL-37 products.
Current sport-status snapshot for LL-37: Not specifically named in the 2026 WADA List; athletes should verify current status and product contents.
Describing an endogenous function does not establish that administering a manufactured product is safe or beneficial.